Overview

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Status:
Active, not recruiting

Trial end date:
2023-03-15

Target enrollment:

Participant gender:

Summary

This phase II, single-arm, multicenter study will evaluate pembrolizumab therapy in patients with advanced triple-negative breast cancer (TNBC) who have received at least one prior line of therapy.

Phase:

Phase 2

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Cyclophosphamide
Pembrolizumab